Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results

The key finding of this phase II trial is that the combination of sorafenib therapy and drug-eluting bead transarterial chemoembolization is safe and effective, especially in patients with advanced hepatocellular carcinoma who were able continue sorafenib therapy for more than 6 months.